CompanyGraph
Shandong Weigao Blood Purification Products Co. Ltd.
603014 · SSE · China
wego-healthcare.comFinancials as of FY2025
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $2.07B, above the global median of $1.15B
- FinancialsAltman Z-Score 7.01: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
2.16%
Annual Rate
CNY 0.72Paid semi-annual
Payout Ratio
13.1%Sustainable
Payback Period
62.7 yr
Last Ex-Dividend
Jun 1, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
13.95BCNY2.07B · vs all stocks (USD)
Trailing P/E
27.83xvs Medical Devices peers
Revenue (TTM)
3.78BCNY561.68M · vs all stocks (USD)
Profit Margin
12.93%vs Medical Devices peers
52-Week Change
-15.44%vs all stocks
Forward Annual Dividend Yield
2.16%vs all stocks
Market Capitalization
13.95BCNY2.07B · vs all stocks (USD)
Enterprise Value
10.90BCNY1.62B · vs all stocks (USD)
Trailing P/E
27.83xvs Medical Devices peers
Forward P/E
25.30xvs Medical Devices peers
Price to Sales (TTM)
3.69xvs Medical Devices peers
Price to Book (MRQ)
1.92xvs Medical Devices peers
Enterprise to Revenue
2.88xvs Medical Devices peers
Enterprise to EBITDA
13.77xvs Medical Devices peers
Gross Margin
38.92%vs Medical Devices peers
Profit Margin
12.93%vs Medical Devices peers
Operating Margin
15.14%vs Medical Devices peers
Return on Assets (TTM)
4.39%vs Medical Devices peers
Return on Equity (TTM)
7.53%vs Medical Devices peers
Revenue (TTM)
3.78BCNY561.68M · vs all stocks (USD)
Revenue per Share (TTM)
9.27CNYUpdated Aug 21, 2026Quarterly Revenue Growth
0.90%vs Medical Devices peers
Gross Profit (TTM)
1.50BCNY222.42M · vs all stocks (USD)
EBITDA (TTM)
570.90MCNY84.90M · vs all stocks (USD)
Net Income (TTM)
488.24MCNY72.61M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
5.30%vs Medical Devices peers
Operating Cash Flow (TTM)
700.45MCNY104.16M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
448.51MCNY66.70M · vs all stocks (USD)
Forward Annual Dividend Rate
0.7216CNYUpdated Aug 21, 2026Forward Annual Dividend Yield
2.16%vs all stocks
Trailing Annual Dividend Rate
0.5184CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
1.55%vs all stocks
Payout Ratio
13.13%vs Medical Devices peers
Minority Interest (Equity)
14.34KCNYFY2025 · Dec 31, 2025Revenue
3.77BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
2.25BCNYFY2025 · Dec 31, 2025Gross Profit
1.52BCNYFY2025 · Dec 31, 2025Operating Income
557.04MCNY82.84M · vs all stocks (USD)
Pre-tax Income
575.82MCNYFY2025 · Dec 31, 2025Income Tax Expense
93.51MCNYFY2025 · Dec 31, 2025Net Income
482.31MCNYFY2025 · Dec 31, 2025EBIT
576.57MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
828.19MCNYFY2025 · Dec 31, 2025Research & Development
143.86MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
398.70MCNYFY2025 · Dec 31, 2025Other Operating Expenses
52.63MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
2.14MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
743.12KCNYFY2025 · Dec 31, 2025Net Income from Continuing Operations
482.31MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-14.34KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
433.92MCNYFY2025 · Dec 31, 2025Free Cash Flow
274.38MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.14BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
482.31MCNYFY2025 · Dec 31, 2025Other Non-cash Items
3.91MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
22.55MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-74.85MCNYFY2025 · Dec 31, 2025Capital Expenditures
-159.54MCNYFY2025 · Dec 31, 2025Purchase of Investments
-10.60BCNYFY2025 · Dec 31, 2025Sale of Investments
9.27BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-1.49BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-65.83MCNYFY2025 · Dec 31, 2025Other Financing Charges
1.11BCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
1.04BCNYFY2025 · Dec 31, 2025Shares Outstanding
417.75MSharesUpdated Aug 21, 2026Float Shares
65.16MSharesUpdated Aug 21, 2026% Held by Insiders
78.71%vs all stocks
% Held by Institutions
4.50%vs all stocks
Total Cash (MRQ)
2.78BCNY413.73M · vs all stocks (USD)
Total Cash per Share (MRQ)
6.66CNYUpdated Aug 21, 2026Total Debt (MRQ)
16.89MCNY2.51M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0023xvs Medical Devices peers
Current Ratio (MRQ)
3.71xvs Medical Devices peers
Book Value per Share (MRQ)
17.36CNYUpdated Aug 21, 2026Total Assets
8.61BCNY1.28B · vs all stocks (USD)
Total Current Assets
4.67BCNYFY2025 · Dec 31, 2025Total Liabilities
1.49BCNYFY2025 · Dec 31, 2025Total Non-current Assets
3.93BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
74.39MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.42BCNYFY2025 · Dec 31, 2025Cash
1.14BCNYFY2025 · Dec 31, 2025Cash Equivalents
442.90MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.58BCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.22BCNYFY2025 · Dec 31, 2025Accounts Receivable
862.49MCNYFY2025 · Dec 31, 2025Inventory
823.25MCNYFY2025 · Dec 31, 2025Accounts Payable
570.40MCNYFY2025 · Dec 31, 2025Short-term Debt
2.90MCNYFY2025 · Dec 31, 2025Other Current Liabilities
125.72MCNYFY2025 · Dec 31, 2025Long-term Debt
30.29KCNYFY2025 · Dec 31, 2025Common Stock (Book)
417.75MCNYFY2025 · Dec 31, 2025Retained Earnings
1.73BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
7.12BCNY1.06B · vs all stocks (USD)
52-Week Low
29.70CNYUpdated Aug 21, 202652-Week High
49.01CNYUpdated Aug 21, 202652-Week Change
-15.44%vs all stocks
50-Day MA
33.54CNYUpdated Aug 21, 2026200-Day MA
37.51CNYUpdated Aug 21, 2026Avg 10-Day Volume
1.89MSharesUpdated Aug 21, 2026Avg 30-Day Volume
2.17MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
1.20CNYUpdated Aug 21, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 7.01: safe zoneNotable
Altman Z-Score: 7.01
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $2.07B, above the global median of $1.15BNotable
Market cap (USD): 2,074,948,518.913Global Median: 1,146,734,693.424
Revenue is $561.68M, above the global median of $520.53MNotable
Revenue (USD): 561,676,822.948Global Median: 520,528,949.311
Levered free cash flow is $66.7M, above the global median of $16.24MNotable
Levered free cash flow (USD): 66,697,282.052Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Monte Rosa Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Mabwell (Shanghai) Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kalbe Farma Tbk. PT
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Ab&B Bio-Tech Co., Ltd. (JS)
Tier 1ProductionApproval-Gated PipelineRule
Verano Holdings Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Aurinia Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
GemPharmatech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Anhui Anke Biotechnology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Hubei Jumpcan Pharmaceutical Co., Ltd.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
CIE Automotive India Ltd.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Manhattan Associates Inc.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities